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Abstract
Background: To study the effect of prophylactic application of mitomycin-C on haze formation
in photorefractive keratectomy (PRK) for high myopia.
Methods: Fifty-four eyes of 28 myopic patients were enrolled in this prospective study. All eyes
were operated by PRK followed by 0.02% mitomycin-C application for two minutes and washed
with 20 ml normal saline afterwards. All eyes were examined thoroughly on the first 7 days and
one month after surgery; 48 eyes (88.9%) at 3 and 6 months postoperatively. Hanna grading (in the
scale of 0 to 4+) was used for assessment of corneal haze.
Results:  The mean spherical equivalent refraction (SE) was -7.08 diopters (D) ± 1.11 (SD)
preoperatively. Six months after surgery, 37 eyes (77.1%) achieved an uncorrected visual acuity
(UCVA) of 20/20 or better, all eyes had a UCVA of 20/40 or better and 45 (93.7%) eyes had an SE
within ± 1.00D. One month postoperatively, 2 eyes (3.7%) had grade 0.5+ of haze, while at 3 and
6 months after surgery no visited eye had haze at all. All eyes had a best corrected visual acuity
(BCVA) of 20/40 or better and there were no lost lines in BCVA by 6 months after surgery. In
spatial frequencies of 6 and 12 cycles per degree contrast sensitivity had decreased immediately
after PRK and it had increased 1.5 lines by the 6th postoperative month compared to the
preoperative data.
Conclusions: The results show the efficacy of mitomycin-C in preventing corneal haze after
treatment of high myopia with PRK. This method- PRK + mitomycin-C – can be considered an
alternative treatment for myopic patients whose corneal thicknesses are inadequate for laser in situ
keratomileusis (LASIK). However, the results should be confirmed in longer follow-ups.
Background
In refractive surgery, patients with -5.00 diopters (D)
myopia or more and corneal thicknesses less than 500 µm
are not suitable candidates for laser in situ keratomileusis
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(LASIK) or conventional photorefractive keratectomy
(PRK) due to the inadequate corneal thickness and risk of
haze.[1-13] There are patients in which LASIK may seem
possible, but the low pachymetry reading limits us to a
small ablation zone, and as a result some post-LASIK com-
plications such as glare and halos may occur. [14] If haze
following PRK can be prevented in myopic eyes with a
spherical equivalent (SE) over -5.00 D, obviously there
would be less concern about the corneal thickness, abla-
tion zone, and even the flap induced aberrations follow-
ing Lasik. [15] Haze after PRK may result from the corneal
wound healing process. In animal models, it has been
shown that this process is probably initiated by keratocyte
apoptosis and the subsequent over-proliferation of cells.
[16] Collagen type IV alpha 3 is also an important factor
in the development of corneal haze after PRK. [16] Mito-
mycin-C is an antibiotic with anti-metabolite effects that
inhibit the proliferation of keratocytes,[17] but it has no
effect on normal epithelial cells of the cornea. Mitomycin-
C 0.02% has been used in the treatment of post-PRK haze.
[18] There are also some reports on the prophylactic use
of mitomycin-C to prevent haze following PRK in moder-
ate to high myopia. [14,19]
In this prospective non-controlled clinical study we have
assessed the prophylactic application of mitomycin-C on
regression and haze in PRK performed on patients with
high myopia (SE ≥ -5.00 D).
Methods
Study design and patient selection
Fifty-four eyes in 28 patients with a spherical equivalent
refraction over -5.00 D were included in this prospective
non-controlled clinical study. Since the residual stromal
bed thickness under the flap after LASIK would be less
than 250 µm, no eye had an appropriate corneal thickness
for this procedure. In planning PRK, the post-ablation cor-
neal thickness was calculated to be greater than 350 µm.
Exclusion criteria in this study were systemic or ocular dis-
ease with the potential to interfere with the healing proc-
ess of the cornea, such as collagenosis, diabetes, dry-eye
syndrome, anterior or posterior uveitis, ectatic diseases
such as keratoconus, and also corneal dystrophy or degen-
eration, glaucoma, retinal diseases, lens opacity, history of
severe ocular trauma, and previous ocular surgery. The
study was approved by the Research and Ethics Commit-
tee of the Noor Vision Correction Center. Before the oper-
ation, the nature of the procedures, their results and
complications were thoroughly explained to all patients
and they were asked to read and sign a formal informed
consent in their native language.
Procedure
All treatments were performed between April and October
2002. All eyes underwent the standard PRK procedure by
two surgeons with extensive experiences with PRK.
Patients received topical anesthesia without systemic
sedation. Pre-incision of the corneal epithelium was made
using a microtrephine with an 8 mm diameter and 70 µm
deep calibrated blade (Janach, J 2900S). The epithelium
was removed mechanically with a hocky knife. Then, the
ablation was performed using a Technolas 217-C excimer
laser (Bausch and Lomb, CA, USA). In all treatments, the
overall ablation diameter was 8.4 to 8.9 mm and con-
sisted of a central optical zone of 5.5 to 6.0 mm respec-
tively by a 2.9 mm transition zone. Considering our
previous experiences, eyes receiving mitomycin-C were
intentionally under-corrected by 5 % compared with
LASIK nomogram.
Immediately after laser ablation, a single topical applica-
tion of mitomycin-C 0.02% (0.2 mg/ml) diluted in bal-
anced salt solution was instilled in each eye with a weck
sponge placed over the ablated stroma for 2 minutes. The
corneal surface and the entire conjunctiva were then vig-
orously irrigated with 20 ml cold normal saline to remove
the residual mitomycin-C. At the end of the procedure, a
bandage contact lens was applied which was removed
after three days.
After surgery, patients were instructed to take an analgesic
(diclofenac sodium) every 8 hours and all eyes received
artificial tears and flourometholone eye drop every four
hours for 2 weeks, and chloramphenicol eye drop every 6
hours for 3 days. During the next two weeks, all patients
were treated with flourometholone and artificial tears
every 6 hours. These two eye drops were used every 8 and
12 hours during the second and third postoperative
months, respectively, and were then discontinued. All
patients were instructed to wear sunglasses in direct sun-
light for 3 months.
The preoperative visit included uncorrected visual acuity
(UCVA), best-corrected visual acuity (BCVA), manifest,
subjective, and cycloplegic refractions, slit-lamp exams,
applanation tonometry, corneal topography, ultrasonic
pachymetry, keratometry, indirect funduscopy, and con-
trast sensitivity with and without glare. UCVA and BCVA
were tested with the Snellen chart. On the first seven days
after surgery, all patients were examined with a slit lamp
and the area of the epithelial defect was measured with its
ruler to identify the time of complete reepithelialization.
On the 7th and 14th days after surgery we measured the
UCVA, BCVA, and the manifest, subjective, and cyclople-
gic refraction. At the 1st, 2nd, and 6th  postoperative
months, exams and measurements included UCVA,
BCVA, manifest, subjective, and cycloplegic refraction,
slit-lamp exams, applanation tonometry, ultrasonic
pachymetry, keratometry, topography, and contrast sensi-
tivity with and without glare. For evaluation of haze weBMC Ophthalmology 2004, 4:12 http://www.biomedcentral.com/1471-2415/4/12
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used Hanna's grading scale from 0 (no haze) to 4+ (dense
white corneal haze). Contrast sensitivity was tested by
Vector Vision CSV-1000 (Vector Vision, Dayton, OH) in
spatial frequencies of 6 (B) and 12 (C) cycles per degree.
[20] The manufacturer's recommended testing procedures
were followed. Absolute values of log contrast sensitivity
were obtained for each patient and spatial frequency, and
means and standard deviations were calculated. Data were
then expressed in the notation of normalized log contrast
sensitivity values. [21]
Statistical analysis
Repeated measures analysis of variance was used to assess
changes over time after surgery. For all statistical tests, the
significance level was considered 0.05.
Results
Of the 28 study group patients, 3 did not show up on the
3rd and 6th months visits (48 eyes out of 54 were visited;
88.9%). The mean age was 29.3 years (range, 20 to 45
years). The mean preoperative SE was -7.08 D ± 1.11 (SD)
(range, -9.88 to -5.00D). The mean preoperative corneal
thickness was 488.6 µm ± 11.9 (SD). At the first, 3rd, and
6th month after surgery, the mean corneal thickness was
357 µm ± 30 (SD), 373 µm ± 27 (SD), and 380 µm ± 28
(SD), respectively. Thirty-three eyes (61.1 %) had a preop-
erative BCVA of 20/20 or better, and 51 eyes (94.4 %) had
a BCVA of 20/25 or better. Complete reepithelialization
was seen in no eye by the 2nd postoperative day but in all
eyes by the 6th day. The epithelial defect had resolved in
53.7 % of the eyes by the 3rd day, and in 92.6 % by the
4th postoperative day.
Figure 1 shows the refractive results in this study group. At
the 3rd postoperative month, 33 eyes (68.7 %) were within
± 0.5 D of emmetropia (SE) and 43 eyes (89.6 %) within
± 1.00D (SE). At the 6th postoperative month 39 eyes
(81.3 %) were within ± 0.5D of emmetropia and 45 eyes
(93.7 %) within ± 1.00D. Figure 2 shows the refractive
changes after surgery during these six months. The refrac-
tion of patients had already become stable one month
after surgery.
At the 3rd postoperative month 32 eyes (66.7 %) had a
UCVA of 20/20 or better and 47 (97.7 %) of 20/40 or bet-
ter. All eyes had a BCVA of 20/40 or better and there were
no lost lines in BCVA. On the 6th month visit, 37 eyes
(77.1 %) had a UCVA of 20/20 or better and 48 (100%)
of 20/40 or better. All eyes had a UCVA of 20/40 or better.
On the first month follow-up visit, 2 eyes (3.7%) had +0.5
haze, but all had 0 haze on the 3rd and 6th month visits.
Figure 3 shows the changes of contrast sensitivity in spa-
tial frequencies of 6 and 12 cycles per degree (CPD) with
and without glare over time. In the spatial frequency of 6
CPD, contrast sensitivity had decreased immediately after
PRK and it had increased by the 6th postoperative month
compared to preoperative data while in the spatial fre-
quency of 12 CPD, it had increased over time after surgery
(P < 0.001).
In our study, no complications such as eccentric ablation,
delayed reepithelialization, persistent epithelial defect, or
microbial keratitis have been observed.
Scatter plots of attempted refractive changes versus the  achieved refractive changes at 6 months after surgery (D =  diopter) Figure 1
Scatter plots of attempted refractive changes versus the 
achieved refractive changes at 6 months after surgery (D = 
diopter).
Mean manifest spherical equivalent refraction changes  (diopter) over time Figure 2
Mean manifest spherical equivalent refraction changes 
(diopter) over time.BMC Ophthalmology 2004, 4:12 http://www.biomedcentral.com/1471-2415/4/12
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Discussion
PRK in high myopia remains a challenge due to its com-
plications of haze and regression reported in previous
experiments, and also the success rate of LASIK in these
patients. [19] Yet, LASIK cannot be performed in some
patients with an insufficient corneal thickness resulting in
an undesirable residual stromal bed, or smaller ablation
zones had to be applied to correct the refractive error com-
pletely. Such a small ablation zone can lead to visual
inconveniences such as impaired night vision when the
pupil dilates, halos, blurred vision, and ghost images.
[15,22] If PRK plus mitomycin-C safety and predictability
can be verified, larger ablation zones can be used, there-
fore the above complications will practically be avoided.
On the other hand, correction of higher refractive errors
will be possible.
This study was carried out to evaluate the safety and effi-
cacy of PRK along with a 2-minute application of mitomy-
cin-C 0.02% (0.2 mg/ml) on the exposed stromal bed
after ablation was performed. Mitomycin-C is an antime-
tabolite and antibiotic drug. It is mostly used systemically
in cancer chemotherapy. It has been used in ophthalmol-
ogy in cases of intraepithelial neoplasms of the cornea
and conjunctiva, ocular pemphygoid, and following sur-
gical treatment of glaucoma and pterygium. Mitomycin-C
has cytotoxic effects through inhibiting DNA synthesis.
The logic behind using mitomycin-C is that the topical
application of the drug on the cornea can inhibit subepi-
thelial fibrosis through preventing the proliferation of
stromal keratocytes, while the main causes of regression
and haze are overacitvity and proliferation of stromal
keratocytes following laser ablation. [19] The effects of
mitomycin-C 0.02% in preventing haze has been shown
by Talamo et al [22], and Xu et al [23] in experimental
models. In a study by Majmudar et al, it was concluded
that the application of mitomycin-C can remove haze fol-
lowing PRK and radial keratectomy (RK). [18] The useful-
ness of PRK with mitomycin-C (0.2 mg/ml) for
preventing haze in high myopia was reported by Carones
et al. [19] In this study we used the same concentration of
0.2 mg/ml to perform PRK + mitomycin-C in high myo-
pia; considering the different climate and races in this
Middle Eastern region. It seems that the problems of haze
and regression after PRK are more prominent in people of
this region. [24] In addition, the inclusion criteria aimed
at patients who were at a relatively high risk of haze for-
mation after PRK. Among factors determining the abla-
tion depth, an important predictor of haze, correction and
ablation zone size are more important. A 6.0 mm optical
zone and a minimum of 5.00 diopters of correction ethi-
cally and practically limited our study to those patients
who were at a high risk of developing haze with PRK.
No immediate toxic effects such as conjunctival chemosis
or any delay or irregularity in re-epithelialization were
seen. In only one case, after primary reepithelialization a
large epithelial defect was seen on the fourth day (one day
after complete epithelialization and contact lens
removal), which healed in three days by applying a band-
age contact lens. No complications such as corneal
edema, melting, and perforation were observed in follow-
up visits up to six months. Therefore, the topical applica-
tion of mitomycin-C of the aforementioned concentra-
tion and duration was safe in our series. Yet, a longer
follow-up is required to assess the long-term complica-
tions of mitomycin-C, and its careful application is rec-
ommended before long-term complications can be ruled
out.
According to our previous experiences, we planned a 5%
under-correction compared to our usual nomogram for
LASIK. As a result of this modification, patients were close
to emmetropia with a low variability on their 6th month
visit. In the report by Carones, patients had a hyperopic
shift of +0.5D by the sixth month; this is while our
patients had a myopic shift of 0.43D.
The UCVA at six months after surgery was 20/40 or better
in 100% and 20/20 or better in 77.1% of patients. The
refractive and visual results of this study are much better
compared to reports concerning the same amount of cor-
rection with LASIK, [25,26] PRK, or LASEK [27,28].
Considering the fact that haze influences BCVA, patients'
BCVA is of great importance. In this study, no eyes lost any
lines of BCVA by six months after surgery compared to the
preoperative BCVA. None of the eyes had any grade of
haze 3 or 6 months after surgery, which shows the efficacy
of prophylactic application of mitomycin-C in preventing
haze following PRK for patients with myopia over -5.00D.
In addition, an average postoperative improvement in
The changes of contrast sensitivity in spatial frequencies of 6  and 12 cycles per degree with and without glare over time  (CPD = cycles per degree; M = month; D = diopter) Figure 3
The changes of contrast sensitivity in spatial frequencies of 6 
and 12 cycles per degree with and without glare over time 
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contrast sensitivity of 1.5 lines points to the safety and
efficacy of the procedure in the quality of vision.
In conclusion, using mitomycin-C in PRK for myopia
greater than -5.00D seems safe and effective, and can
reduce haze formation after surgery; therefore it can be
considered a suitable alternative for patients with myopia
greater than -5.00 D whose corneas lack an appropriate
thickness to perform LASIK with a desirable optical zone.
With this method, vision can be corrected with a better
quality of vision regarding contrast sensitivity.
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